Poland Liver Diseases Therapeutics Market Report 2022 to 2030

Poland Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Poland liver disease therapeutics market will reach a value of $216 Mn from $134 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030. The liver disease therapeutics in Poland is dominated by a few domestic pharmaceutical companies such as Polpharma, Adamed, and Hasco-Lek. The liver disease therapeutics market in Poland is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10PLPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Dr. Vishwa Modhia

Buy Now

Poland Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Poland liver disease therapeutics market will reach a value of $216 Mn from $134 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030.

Poland is a high-income, developed country in Central Europe bordered by Belarus, the Czech Republic, Germany, Lithuania, Russia, Slovakia, and Ukraine. In Poland, liver illness is a major public health concern, with viral hepatitis being one of the biggest causes. In Poland, the prevalence of chronic hepatitis B is believed to be around 0.3 %, whereas the prevalence of chronic hepatitis C is expected to be around 0.5 %. Both disorders can result in liver cirrhosis and cancer. Other variables, such as alcohol consumption, obesity, and non-alcoholic fatty liver disease (NAFLD), in addition to viral hepatitis, are contributing to the rising incidence of liver disease in Poland. A study published in the Journal of Clinical Gastroenterology found that the prevalence of NAFLD in Poland was around 18%.

According to the latest WHO data published in 2020 liver disease deaths in Poland reached 7,912 or 2.22% of total deaths. The age-adjusted death rate is 14.35 per 100,000 of the population ranks Poland 110^th in the world. Poland's government spent 6.5 % of its GDP on healthcare in 2020.

poland liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

In 2020, 2,854 instances of hepatitis B were reported, resulting in an incidence of 2.59 per 100,000 population, which is 65.1 % lower than in 2019. The Polish Liver Research Association has advocated for enhanced efforts in Poland to prevent and manage NAFLD, such as raising awareness of the condition among healthcare professionals and the general public, as well as increasing funding for research and development of new treatments. NAFLD affects around 20-30% of the Polish population, according to the Polish Liver Research Association. Poland's economy is diverse, and it is located near Western European markets (agriculture, a variety of industries, and services).

Market Restraints

Greater knowledge and education on liver disease prevention and management are required, particularly with regard to lifestyle strategies such as lowering alcohol intake and supporting healthy diets. Poland, in general, does not invest in R&D and imports a significant portion of its exports.

Competitive Landscape

Key Players

Polpharma: Polpharma is the largest Polish pharmaceutical company that produces a wide range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid
Adamed: Adamed is a Polish pharmaceutical company that produces a variety of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid
Hasco-Lek: Hasco-Lek is a Polish pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silibinin
Biomed Lublin: Biomed Lublin is a Polish pharmaceutical company that produces a range of therapeutic products, including those for liver disease

Recent Notable Updates

December 2022: Apeiron Synthesis, a Polish deep-tech business aiming to create unique and revolutionary chemical solutions, is co-financed by Adamed. Apeiron Synthesis, a Polish deep tech firm with the goal of providing unique and revolutionary chemical solutions, is co-financed by Adamed.

Healthcare Policies and Reimbursement Scenarios

In Poland, the regulation of liver disease therapeutics is overseen by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) and the Chief Pharmaceutical Inspectorate (GIF), which are responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, meet safety, efficacy, and quality standards. To be approved for use in Poland, liver disease therapeutics must be registered with the URPL, and manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory requirements. In terms of reimbursement, the National Health Fund (NFZ) is responsible for providing health insurance coverage to Polish citizens.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Poland Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.